Cancer of the Peripheral Nerve in Neurofibromatosis Type 1

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Neurotherapeutics

• Publication date

  2017-03-27

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s13311-017-0518-yPMID 28349408PMCID PMC5398990
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Patterns of recurrence and survival in sporadic, neurofibromatosis Type 1-associated, and radiation-associated malignant peripheral nerve sheath tumors.

  2017cited by this paper
• Characterizing the immune microenvironment of malignant peripheral nerve sheath tumor by PD-L1 expression and presence of CD8+ tumor infiltrating lymphocytes

  2016cited by this paper
• Overexpression of PDGFRA cooperates with loss of NF1 and p53 to accelerate the molecular pathogenesis of malignant peripheral nerve sheath tumors

  2016cited by this paper
• Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.

  2016cited by this paper
• The Challenge of Cancer Genomics in Rare Nervous System Neoplasms: Malignant Peripheral Nerve Sheath Tumors as a Paradigm for Cross-Species Comparative Oncogenomics.

  2016cited by this paper
• PD-1 blockade in tumors with mismatch repair deficiency.

  2015cited by this paper
• PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.

  2015cited by this paper
• Clostridium novyi-NT can cause regression of orthotopically implanted glioblastomas in rats

  2015cited by this paper
• A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor

  2015cited by this paper
• BET bromodomain inhibition triggers apoptosis of NF1-associated malignant peripheral nerve sheath tumors through Bim induction.

  2014cited by this paper
• Intratumoral injection of Clostridium novyi-NT spores induces antitumor responses

  2014cited by this paper
• PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors

  2014cited by this paper
• Sustained Inhibition of Receptor Tyrosine Kinases and Macrophage Depletion by PLX3397 and Rapamycin as a Potential New Approach for the Treatment of MPNSTs

  2014cited by this paper
• Remission of disseminated cancer after systemic oncolytic virotherapy.

  2014cited by this paper
• PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies

  2014cited by this paper
• Overexpression of Cyclooxygenase-2 in Malignant Peripheral Nerve Sheath Tumor and Selective Cyclooxygenase-2 Inhibitor-Induced Apoptosis by Activating Caspases in Human Malignant Peripheral Nerve Sheath Tumor Cells

  2014cited by this paper
• Neurofibromin in neurofibromatosis type 1 - mutations in NF1gene as a cause of disease.

  2014cited by this paper
• Radiation Therapy in Management of Sporadic and Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumors

  2014cited by this paper
• The VEGF- and PDGF-family of angiogenic markers have prognostic impact in soft tissue sarcomas arising in the extremities and trunk

  2014cited by this paper
• EGFR–STAT3 signaling promotes formation of malignant peripheral nerve sheath tumors

  2014cited by this paper
• 18‐fluorodeoxyglucose‐positron emission tomography (FDG‐PET) evaluation of nodular lesions in patients with neurofibromatosis type 1 and plexiform neurofibromas (PN) or malignant peripheral nerve sheath tumors (MPNST)

  2013cited by this paper
• Systemic Image-Guided Liver Cancer Radiovirotherapy Using Dendrimer-Coated Adenovirus Encoding the Sodium Iodide Symporter as Theranostic Gene

  2013cited by this paper
• CXCR4/CXCL12 mediate autocrine cell- cycle progression in NF1-associated malignant peripheral nerve sheath tumors.

  2013cited by this paper
• Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and genetic pathways driving tumorigenesis

  2013cited by this paper
• Schwannoma in neurofibromatosis type 1: a pitfall for detecting malignancy by metabolic imaging

  2013cited by this paper
• SARC006: Phase II trial of chemotherapy in sporadic and neurofibromatosis type 1 (NF1)-associated high-grade malignant peripheral nerve sheath tumors (MPNSTs).

  2013cited by this paper
• Benign whole body tumor volume is a risk factor for malignant peripheral nerve sheath tumors in neurofibromatosis type 1

  2013cited by this paper
• MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors.

  2013cited by this paper
• Ras-Driven Transcriptome Analysis Identifies Aurora Kinase A as a Potential Malignant Peripheral Nerve Sheath Tumor Therapeutic Target

  2012cited by this paper
• Neurofibroma-associated macrophages play roles in tumor growth and response to pharmacological inhibition

  2012cited by this paper
• Pathology of peripheral nerve sheath tumors: diagnostic overview and update on selected diagnostic problems

  2012cited by this paper
• Malignant Peripheral Nerve Sheath Tumors (MPNST): The Mayo Clinic Experience

  2012cited by this paper
• Tumor microenvironment induces innate RAF-inhibitor resistance through HGF secretion

  2012cited by this paper
• Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors.

  2011cited by this paper
• Activated MET Is a Molecular Prognosticator and Potential Therapeutic Target for Malignant Peripheral Nerve Sheath Tumors

  2011cited by this paper
• Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors

  2011cited by this paper
• MRI features in the differentiation of malignant peripheral nerve sheath tumors and neurofibromas.

  2010cited by this paper
• NF1 microdeletions in neurofibromatosis type 1: from genotype to phenotype

  2010cited by this paper
• Results of a Sarcoma Alliance for Research through Collaboration (SARC) phase II trial of dasatinib in previously treated, high-grade, advanced sarcoma.

  2010cited by this paper
• Molecular targets for cancer chemoprevention

  2009cited by this paper
• Clinical, Pathological, and Molecular Variables Predictive of Malignant Peripheral Nerve Sheath Tumor Outcome

  2009cited by this paper
• Phase II study of sorafenib in patients with metastatic or recurrent sarcomas.

  2009cited by this paper
• Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model.

  2009cited by this paper
• PDGFRA, PDGFRB, EGFR, and downstream signaling activation in malignant peripheral nerve sheath tumor.

  2009cited by this paper
• Unravelling the genetic basis of variable clinical expression in neurofibromatosis 1.

  2009cited by this paper
• Survival in Malignant Peripheral Nerve Sheath Tumours: A Comparison between Sporadic and Neurofibromatosis Type 1-Associated Tumours

  2009cited by this paper
• Nf1-dependent tumors require a microenvironment containing Nf1+/-- and c-kit-dependent bone marrow.

  2008cited by this paper
• Frequent EGFR Positivity and Overexpression in High-Grade Areas of Human MPNSTs

  2008cited by this paper
• The role of radiation therapy in the management of sarcomas.

  2008cited by this paper
• Nerve injury signaling.

  2008cited by this paper
• Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1.

  2008cited by this paper
• EGFR and erbB2 in malignant peripheral nerve sheath tumors and implications for targeted therapy.

  2008cited by this paper
• Imatinib mesylate inhibits cell invasion of malignant peripheral nerve sheath tumor induced by platelet-derived growth factor-BB

  2007cited by this paper
• Phase II study of erlotinib in metastatic or unresectable malignant peripheral nerve sheath tumors (MPNST).

  2006cited by this paper
• Mutation and expression of PDGFRA and KIT in malignant peripheral nerve sheath tumors, and its implications for imatinib sensitivity.

  2006cited by this paper
• Neurofibromatosis type 1 — a model for nervous system tumour formation?

  2005cited by this paper
• Pharmacologic and toxicologic evaluation of C. novyi-NT spores.

  2005cited by this paper
• Role for the epidermal growth factor receptor in neurofibromatosis-related peripheral nerve tumorigenesis.

  2005cited by this paper
• Differentially expressed genes in neurofibromatosis 1-associated neurofibromas and malignant peripheral nerve sheath tumors

  2004cited by this paper
• Sulindac derivatives inhibit cell growth and induce apoptosis in primary cells from malignant peripheral nerve sheath tumors of NF1-patients

  2004cited by this paper
• Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy.

  2004cited by this paper
• Bacteriolytic therapy can generate a potent immune response against experimental tumors.

  2004cited by this paper
• Neurofibromin-deficient Schwann cells secrete a potent migratory stimulus for Nf1+/- mast cells.

  2003cited by this paper
• Elevated risk for MPNST in NF1 microdeletion patients.

  2003cited by this paper
• Inflammation and cancer

  2002cited by this paper
• Angiogenesis stimulated by PDGF-CC, a novel member in the PDGF family, involves activation of PDGFR-alphaalpha and -alphabeta receptors.

  2002cited by this paper
• Malignant peripheral nerve sheath tumours in neurofibromatosis 1

  2002cited by this paper
• Angiogenesis stimulated by PDGF‐CC, a novel member in the PDGF family, involves activation of PDGFR‐aa and ‐ap receptors

  2002cited by this paper
• 腱移行術による機能再建を施行した橈骨神経本幹の Malignant Peripheral Nerve Sheath Tumor(MPNST)

  2001cited by this paper
• Combination bacteriolytic therapy for the treatment of experimental tumors

  2001cited by this paper
• Cell signaling by receptor tyrosine kinases.

  2000cited by this paper
• Cell signaling by receptor tyrosine kinases.

  2000cited by this paper
• Epidermal growth factor receptor expression in neurofibromatosis type 1-related tumors and NF1 animal models.

  2000cited by this paper
• The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2.

  1997cited by this paper
• The Neurofibromatoses : a pathogenetic and clinical overview

  1994cited by this paper
• National Institutes of Health Consensus Development Conference Statement: neurofibromatosis. Bethesda, Md., USA, July 13-15, 1987.

  1988cited by this paper
• The Genetic Aspects of Neurofibromatosis a

  1986cited by this paper
• [Inflammation and cancer].

  1974cited by this paper

• Intratumoral plasma cells mediate CD8+ T cell infiltration and successful immune checkpoint blockade therapy in de novo MPNSTs

  2026cites this paper
• Utilization of PET/MR Imaging and PET/CT in Uncommon Pediatric Disease.

  2026cites this paper
• Novel Therapeutics and the Path Toward Effective Immunotherapy in Malignant Peripheral Nerve Sheath Tumors

  2025cites this paper
• Recurrent giant malignant peripheral nerve sheath tumor of the scalp: A case report

  2025cites this paper
• Clinical and genomic profiles of malignant peripheral nerve sheath tumors in the craniospinal axis

  2025cites this paper
• Emerging mechanism and therapeutic potential of neurofibromatosis type 1-related nerve system tumor: Advancing insights into tumor development

  2025cites this paper
• Pathologic and Therapeutic Schwann Cells

  2025cites this paper
• Conditionally replicative adenovirus as a therapy for malignant peripheral nerve sheath tumors

  2024cites this paper
• [Analysis of clinical features, treatment methods, and prognostic influence factors in patients with malignant peripheral nerve sheath tumor].

  2024cites this paper
• Myelomodulatory treatments augment the therapeutic benefit of oncolytic viroimmunotherapy in murine models of malignant peripheral nerve sheath tumors

  2024cites this paper
• Non-Mammalian Models for Understanding Neurological Defects in RASopathies

  2024cites this paper
• A rare Encounter with Pediatric Malignant Peripheral Nerve Sheath Tumor in Nasal Sinuses and Orbit

  2024cites this paper
• p53 modulates kinase inhibitor resistance and lineage plasticity in NF1-related MPNSTs

  2023cites this paper
• Direct comparison of the diagnostic accuracy of 2-[18F]-fluoro-2-deoxy-d-glucose PET/CT and MRI for the differentiation of malignant peripheral nerve sheath tumour in neurofibromatosis type I: a meta-analysis.

  2023cites this paper
• FOXM1, MEK, and CDK4/6: New Targets for Malignant Peripheral Nerve Sheath Tumor Therapy

  2023influential citation
• CDK4/6-MEK inhibition in MPNSTs causes plasma cell infiltration, sensitization to PD-L1 blockade, and tumor regression.

  2023cites this paper
• Giant Cell Lesions of the Jaws Involving RASopathy Syndromes

  2022influential citation
• Lumbar malignant peripheral nerve sheath tumor: a rare case in a young patient

  2022cites this paper
• Diagnostic value of 18F-FDG PET-CT in detecting malignant peripheral nerve sheath tumors among adult and pediatric neurofibromatosis type 1 patients

  2022cites this paper
• Epidemiology of Peripheral Nerve Sheath Tumors

  2021cites this paper
• Diagnostic Accuracy of MRI for the Detection of Malignant Peripheral Nerve Sheath Tumors: A Systematic Review and Meta-Analysis.

  2021cites this paper
• Somatic Genomic Defects And Tumor Progression In NF1-associated Tumors 

  2021cites this paper
• A Review of Selumetinib in the Treatment of Neurofibromatosis Type 1–Related Plexiform Neurofibromas

  2021cites this paper
• Neurofibromatosis: Molecular Pathogenesis and Natural Compounds as Potential Treatments

  2021cites this paper
• Malignant peripheral nerve sheath tumor of the infratemporal fossa: Case report and literature review

  2021cites this paper
• Imaging Features of Neurofibromatosis Type 1 in the Abdomen and Pelvis.

  2020cites this paper
• Metastatic Malignant Peripheral Nerve Sheath Tumor With NF1 Successfully Treated With ‘Gradual Subtraction’ ICE Chemotherapy

  2020cites this paper
• Malignant Peripheral Nerve Sheath Tumor in an Army Reservist With Neurofibromatosis Type 1.

  2020cites this paper
• Neonatal hyperinsulinemic hypoglycemia: case report of kabuki syndrome due to a novel KMT2D splicing-site mutation

  2020cites this paper
• Neurofibromatosis Type 1: New Developments in Genetics and Treatment.

  2020cites this paper
• Preventative Effect of Mebendazole against Malignancies in Neurofibromatosis 1

  2020cites this paper
• Aberrations of TBX2-CHK2-p53 Signaling Pathway and its Role in Malignant Peripheral Nerve Sheath Tumors

  2020cites this paper
• Peripheral Nerve Tumors in Neurofibromatosis 1, Neurofibromatosis 2, and Schwannomatosis

  2020influential citation
• CDKs in Sarcoma: Mediators of Disease and Emerging Therapeutic Targets

  2020cites this paper
• Polo-like kinase 1 as a therapeutic target for malignant peripheral nerve sheath tumors (MPNST) and schwannomas.

  2020cites this paper
• Malignant peripheral nerve sheath tumor of the nasal cavity and nasopharynx in a child

  2019cites this paper
• Histology, Schwann Cells

  2019cites this paper
• Non-Coding RNA and Tumor Development in Neurofibromatosis Type 1: ANRIL Rs2151280 Is Associated with Optic Glioma Development and a Mild Phenotype in Neurofibromatosis Type 1 Patients

  2019cites this paper
• The Novel Glutamine Antagonist Prodrug JHU395 Has Antitumor Activity in Malignant Peripheral Nerve Sheath Tumor

  2019cites this paper
• Feasibility of Using NF1-GRD and AAV for Gene Replacement Therapy in NF1-Associated Tumors

  2019cites this paper
• Treatment and survival differences across tumor sites in malignant peripheral nerve sheath tumors: a SEER database analysis and review of the literature.

  2018cites this paper